‼️ We are moving to LinkedIn ‼️. You can find our LinkedIn account at

The NCPE recommends that durvalumab (Imfinzi®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*(2/2).

The NCPE has completed a full HTA of Durvalumab (Imfinzi®) in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer.(1/2).

human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. A full HTA is not recommended. The NCPE recommends that ribociclib not be considered for reimbursement at the submitted price*.(2/2).

The NCPE have completed a Rapid Review of Ribociclib (Kisqali®) in combination with an aromatase inhibitor (AI) is indicated for the adjuvant treatment of patients with hormone receptor positive (HR+), . (1/2)

A full HTA is not recommended. The NCPE recommends that eplontersen not be considered for reimbursement at the submitted price*.(2/2).

The NCPE have completed a Rapid Review of Eplontersen (Wainzua®) or the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.(1/2)

A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of spesolimab compared with the current standard of care.(2/2).

The NCPE have completed a Rapid Review of Spesolimab (Spevigo®) for the treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherap.(1/2)

The NCPE recommends that selumetinib (Koselugo®) not be considered for reimbursement*. (2/2).

The NCPE have completed a full HTA of Selumetinib (Koselugo®) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above. (1/2)

‼️The NCPE is hiring! Would you be interested in applying for the role of Statistician at the NCPE?. 📊Our Statisticians play a key role in the evaluation of drugs and other HTA related activities!. ⭐️More info at: . ‼️Closing date 15/12/2024

L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI) . A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab compared with the current standard of care. (2/2).

The NCPE have completed a Rapid Review of Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (1/2)

The NCPE recommends that voclosporin (Lupkynis®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

The NCPE has completed a Rapid Review of Voclosporin (Lupkynis®) is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). (1/2)

The use of imlifidase should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients. The NCPE recommends that imlifidase be considered for reimbursement*.(2/2)

The NCPE has completed a full HTA of Imlifidase (Idefirix®) for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. (1/2)

A full HTA is not recommended. The NCPE recommends that tenecteplase be considered for reimbursement*(2/2)